Merck & Co. Inc. on Thursday named a company insider to replace embattled Chief Executive Raymond Gilmartin, a move that was greeted with little enthusiasm by investors who had hoped for a high-profile outsider to turn the drugmaker around.
*For more on this story,
read the full Reuters article.
